Impact of HIV infection, highly active antiretroviral therapy, and hepatitis C coinfection on serum interleukin-27
Guzzo, Christinaa; Hopman, Wilma Mb; Mat, Nor Fazila Chea; Wobeser, Wendyc; Gee, Katrinaa
aDepartment of Microbiology and Immunology, Canada
bDepartment of Community Health and Epidemiology, Canada
cDivision of Infectious Disease, Department of Medicine, Queen's University, Kingston, Ontario, Canada.
Received 30 December, 2009
Revised 15 February, 2010
Accepted 25 February, 2010
Correspondence to Katrina Gee, Department of Microbiology and Immunology, Queen's University, Rm 738 Botterell Hall, Kingston, ON K7L3N6, Canada. E-mail: kgee@queensu,ca
A newly described cytokine, interleukin-27 (IL-27), that activates naive CD4 T cells, has recently been shown to be an anti-HIV cytokine. However, the effect of HIV infection on IL-27 expression has not been characterized. We found that clinical characteristics, including HIV viral load, hepatitis C virus coinfection, and CD4 T cell counts, were associated with changes in serum IL-27. Overall, our results suggest circulating HIV may suppress IL-27, a critical concept in treatment development with this cytokine.
HIV infection causes dysregulated cytokine production [1–5], resulting in impaired immunity characteristic of HIV/AIDS. Interleukin-27 (IL-27) is a newly described IL-12 family cytokine critical in development of Th1 responses [6–8]. IL-27 also regulates inflammatory responses in monocytes/macrophages [9,10] and CD4 T cells [6,11], which are targets of HIV. The effect of HIV on IL-27 has not been investigated. Interestingly, studies have demonstrated that IL-27 can inhibit HIV replication [12–14], leading to the possibility of IL-27 administration as anti-HIV therapy. This study characterizes for the first time how HIV affects IL-27 expression.
In accordance with Queen's University Research Ethics Board, informed consent was obtained from HIV-positive (n = 32) and HIV-negative (n = 11) individuals. Group 1 (n = 6) was naive to highly active antiretroviral therapy (HAART) with a median viral load of 24 927 copies/ml, group 2 (n = 10) was receiving HAART with low viral load (<500 copies/ml), group 3 (n = 9) was receiving HAART with low viral load and coinfected with hepatitis C virus (HCV), and group 4 (n = 7) was receiving HAART with high viral load (>500 copies/ml, median of 3003 copies/ml). Of the group 4 patients, three were tolerant/nonadherent to HAART, two were two-class resistant [nucleoside reverse transcriptase inhibitors (NRTIs) and nonnucleoside reverse transcriptase inhibitors], and one was one-class resistant (NRTI). Ten patients (n = 2, 4, 3, and 1 in groups 1, 2, 3, and 4, respectively) had samples drawn several months apart and, therefore, are included twice to enhance statistical power. CD4 T cell counts and viral loads were obtained during routine clinic visits (Clinical Immunology Outpatient Clinic, Hotel Dieu Hospital, Kingston, Ontario, Canada). Due to the small sample size and nonnormal distribution of key variables, nonparametric tests (Spearman's correlations, Mann–Whitney U-test, Kruskal–Wallis test) were used for analysis, using SPSS, version 17.0 for windows (SPSS Inc., Chicago, Illinois, USA). A P value less than 0.15 was considered a trend of clinical relevance, whereas a P value less than 0.05 was used to define statistical significance.
Heterodimeric IL-27 ELISAs (R&D Systems, Minneapolis, Minnesota, USA) showed considerable variability in IL-27 expression levels among HIV-negative and HIV-positive patient groups (Fig. 1a). Interestingly, group 4 exhibited strikingly low IL-27 expression with minimal variability. Further analysis determined that the overall data were not normally distributed (data not shown); therefore, we performed nonparametric tests based on medians and ranks.
We observed an overall moderate negative correlation between IL-27 and viral load using Spearman's ρ (ρ = −0.201, P = 0.149; Fig. 1b, top). Results were similar (ρ = −0.299) in group 1 (Fig. 1b, middle), but the drop in sample size (from 53 to 8) resulted in a substantial loss of statistical power (P = 0.47). Interestingly, in group 4 (Fig. 1b, bottom), no association was found. Groups 2 and 3 present no detectable viral load and, therefore, were not included. When HIV-infected patients were grouped as either naive to or on HAART (Fig. 1c), the Mann–Whitney test found no difference in the mean rank of IL-27 between the two groups, indicating no association of HAART and HIV viral load.
We investigated whether HCV coinfection might influence IL-27 and observed a decrease in IL-27 in patients coinfected with HCV compared to those monoinfected with HIV (Fig. 1d), which fell just short of statistical significance (P = 0.093). Additionally, we employed the Kruskal–Wallis test among all study participants (overall) and for each of the HIV-infected groups to examine whether IL-27 expression differed with CD4 T cell count (Fig. 1e). The overall group indicated a noteworthy trend of IL-27 expression within CD4 groups (P = 0.153); IL-27 peaked within the moderate CD4 T cell count group (200–350) and decreased in the low CD4 T cell count group (<200). This was a consistent trend of IL-27 within CD4 groups, with moderate CD4 T cell counts (200–350) showing highest IL-27 in four out of five groups.
Recent studies identify IL-27 as an anti-HIV cytokine [12–14], indicating a potential role for IL-27 in the control of HIV replication. Herein, we describe for the first time how IL-27 levels are modulated in HIV infection. We observed a negative correlation between viral load and IL-27; high viral load may suppress IL-27, a pathogenic mechanism used by HIV to downregulate immune responses. This is supported by studies showing low expression of the related cytokine, IL-12, in HIV infection [15,16]. The negative correlation also substantiates previous findings showing IL-27-mediated inhibition of viral replication [12–14]. The loss of the negative correlation in group 4 could be attributed to widespread loss of normal immunologic function and/or the development of tolerance/resistance to HAART. Whether suppression of IL-27 is mediated via host response or directly by HIV remains to be investigated.
We observed no significant difference in IL-27 among patients naive to HAART versus those receiving HAART, consistent with a recent study showing no effect of HAART on the IL-27-related cytokine, IL-12, and its overproduction observed in acute infection . Our finding that HCV coinfection was associated with a significant decrease in IL-27 indicates that HCV may suppress IL-27, paralleling previous studies showing HCV core protein inhibits IL-12 [17–19]. On the contrary, studies have shown enhanced circulating cytokines in HCV infection [20,21], including IL-12, whereby HCV genotype 1 was associated with a significant increase in IL-12 expression . Further work investigating HCV viral loads and genotypes in coinfected participants might provide insight into IL-27 suppression.
We observed CD4 T cell count categories to significantly differ in IL-27 expression. In four out of five groups, a boost in IL-27 from high CD4 T cell counts (>350) to moderate (200–350), followed by a decline in IL-27 at low CD4 cell counts (<200) was observed. We hypothesize the initial boost in IL-27 to indicate host response to viral insult. IL-27 can inhibit HIV replication [12–14,21] and, therefore, upregulating IL-27 could be a protective response to decreasing CD4 T cells and increasing viral load. As disease weakens immunity, the virus may then suppress IL-27.
Our findings indicate HIV viral load, HCV coinfection, and CD4 T cell counts are strongly associated with changes in serum IL-27. This study is the first to report how HIV infection influences IL-27 expression. Understanding how HIV affects IL-27 is a critical step in determining the potential of IL-27 as a therapeutic adjunct to HIV treatments.
The authors would like to thank blood donors for their participation in this study, along with Jenna Ekborn and Catherine Fuller (Clinical Immunology Outpatient Clinic, Hotel Dieu Hospital, Kingston, ON) for their assistance in participant recruitment. This work was supported by a Research Initiation Grant from Queen's University and the Canadian Foundation for Innovation.
C.G. processed serum samples, performed ELISAs, and contributed to concept and study design. W.M.H. performed all statistical analysis and assisted with interpretation of results. N.F.C.M. assisted with the processing of serum samples. W.W. is the director of the immunology clinic at Hotel Dieu Hospital and oversaw sample collection as well as assisted with concept and study design. K.G. is the corresponding author.
C.G. is supported by a studentship from the Ontario HIV Treatment Network.
The authors have no conflicts of interest to declare.
1. Byrnes AA, Harris DM, Atabani SF, Sabundayo BP, Langan SJ, Margolick JB, Karp CL. Immune activation and IL-12 production during acute/early HIV infection in the absence and presence of highly active, antiretroviral therapy. J Leukoc Biol 2008; 84:1447–1453.
2. Tilton JC, Johnson AJ, Luskin MR, Manion MM, Yang J, Adelsberger JW, et al. Diminished production of monocyte proinflammatory cytokines during human immunodeficiency virus viremia is mediated by type I interferons. J Virol 2006; 80:11486–11497.
3. Choe W, Volsky DJ, Potash MJ. Induction of rapid and extensive beta-chemokine synthesis in macrophages by human immunodeficiency virus type 1 and gp120, independently of their coreceptor phenotype. J Virol 2001; 75:10738–10745.
4. Warby TJ, Crowe SM, Jaworowski A. Human immunodeficiency virus type 1 infection inhibits granulocyte-macrophage colony-stimulating factor-induced activation of STAT5A in human monocyte-derived macrophages. J Virol 2003; 77:12630–12638.
5. Dhillon N, Zhu X, Peng F, Yao H, Williams R, Qiu J, et al. Molecular mechanism(s) involved in the synergistic induction of CXCL10 by human immunodeficiency virus type 1 Tat and interferon-gamma in macrophages. J Neurovirol 2008; 14:196–204.
6. Pflanz S, Timans JC, Cheung J, Rosales R, Kanzler H, Gilbert J, et al. IL-27, a heterodimeric cytokine composed of EBI3 and p28 protein, induces proliferation of naive CD4(+) T cells. Immunity 2002; 16:779–790.
7. Hunter CA. New IL-12-family members: IL-23 and IL-27, cytokines with divergent functions. Nat Rev Immunol 2005; 5:521–531.
8. Takeda A, Hamano S, Yamanaka A, Hanada T, Ishibashi T, Mak TW, et al. Cutting edge: role of IL-27/WSX-1 signaling for induction of T-bet through activation of STAT1 during initial Th1 commitment. J Immunol 2003; 170:4886–4890.
9. Pflanz S, Hibbert L, Mattson J, Rosales R, Vaisberg E, Bazan JF, et al. WSX-1 and glycoprotein 130 constitute a signal-transducing receptor for IL-27. J Immunol 2004; 172:2225–2231.
10. Ruckerl D, Hessmann M, Yoshimoto T, Ehlers S, Holscher C. Alternatively activated macrophages express the IL-27 receptor alpha chain WSX-1. Immunobiology 2006; 211:427–436.
11. Owaki T, Asakawa M, Morishima N, Hata K, Fukai F, Matsui M, et al. A role for IL-27 in early regulation of Th1 differentiation. J Immunol 2005; 175:2191–2200.
12. Fakruddin JM, Lempicki RA, Gorelick RJ, Yang J, Adelsberger JW, Garcia-Pineres AJ, et al. Noninfectious papilloma virus-like particles inhibit HIV-1 replication: implications for immune control of HIV-1 infection by IL-27. Blood 2007; 109:1841–1849.
13. Greenwell-Wild T, Vazquez N, Jin W, Rangel Z, Munson PJ, Wahl SM. Interleukin-27 inhibition of HIV-1 involves an intermediate induction of type I interferon. Blood 2009; 114:1864–1874.
14. Imamichi T, Yang J, Huang DW, Brann TW, Fullmer BA, Adelsberger JW, et al. IL-27, a novel anti-HIV cytokine, activates multiple interferon-inducible genes in macrophages. AIDS 2008; 22:39–45.
15. Chehimi J, Starr SE, Frank I, D'Andrea A, Ma X, MacGregor RR, et al. Impaired interleukin 12 production in human immunodeficiency virus-infected patients. J Exp Med 1994; 179:1361–1366.
16. Daftarian MP, Diaz-Mitoma F, Creery WD, Cameron W, Kumar A. Dysregulated production of interleukin-10 (IL-10) and IL-12 by peripheral blood lymphocytes from human immunodeficiency virus-infected individuals is associated with altered proliferative responses to recall antigens. Clin Diagn Lab Immunol 1995; 2:712–718.
17. Eisen-Vandervelde AL, Waggoner SN, Yao ZQ, Cale EM, Hahn CS, Hahn YS. Hepatitis C virus core selectively suppresses interleukin-12 synthesis in human macrophages by interfering with AP-1 activation. J Biol Chem 2004; 279:43479–43486.
18. Lee CH, Choi YH, Yang SH, Lee CW, Ha SJ, Sung YC. Hepatitis C virus core protein inhibits interleukin 12 and nitric oxide production from activated macrophages. Virology 2001; 279:271–279.
19. Waggoner SN, Hall CH, Hahn YS. HCV core protein interaction with gC1q receptor inhibits Th1 differentiation of CD4+ T cells via suppression of dendritic cell IL-12 production. J Leukoc Biol 2007; 82:1407–1419.
20. Schvoerer E, Navas MC, Thumann C, Fuchs A, Meyer N, Habersetzer F, Stoll-Keller F. Production of interleukin-18 and interleukin-12 in patients suffering from chronic hepatitis C virus infection before antiviral therapy. J Med Virol 2003; 70:588–593.
21. Tornero C, Alberola J, Tamarit A, Navarro D. Effect of highly active antiretroviral therapy and hepatitis C virus co-infection on serum levels of pro-inflammatory and immunoregulatory cytokines in human immunodeficiency virus-1-infected individuals. Clin Microbiol Infect 2006; 12:555–560.
This article has been cited 3 time(s).
Plos OneInterleukin-27 Is a Potent Inhibitor of cis HIV-1 Replication in Monocyte-Derived Dendritic Cells via a Type I Interferon-Independent PathwayPlos One
Journal of Experimental MedicineIL-27 inhibits HIV-1 infection in human macrophages by down-regulating host factor SPTBN1 during monocyte to macrophage differentiationJournal of Experimental Medicine
Scientific ReportsIL-27 increases BST-2 expression in human monocytes and T cells independently of type I IFNScientific Reports
© 2010 Lippincott Williams & Wilkins, Inc.